TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02986243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 6 months worth of exercise regimen

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diet Plan
Description: Each subject will receive a personalized diet plan from nutritionist.
Study: NCT01844011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily electronic reminders
Description: Women in the intervention arm will be sent either daily text messages on the weekdays on their cell phone or emails on the weekdays reminding them to track kick counts on the chart
Study: NCT01201616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Low Carbohydrate Diet
Description: 55% total energy intake from fats, 17% from protein and 28% from carbohydrate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fat High Carbohydrate Diet
Description: 20% total energy intake from dietary fats, 17% from protein and 63% from carbohydrate
Study: NCT01514240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D9421-C capsule 3 mg
Description: Patients randomised to D9421-C 9 mg will take 3 capsules of D9421-C capsule 3 mg once daily before breakfast and 4 tablets of Mesalazine tablets placebo three times a day after each meal for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine tablets
Description: Patients randomised to Mesalazine 3 g will take 3 capsules of D9421-C capsule placebo once daily before breakfast and 4 tablets of Mesalazine tablets 250 mg three times a day after each meal for 8 weeks.
Study: NCT03095586

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: News items with spin
Description: Interpretation of news items with spin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: News items without spin
Description: Interpretation of news items without spin
Study: NCT02615405

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EPA
Description: A daily treatment of 5 identical capsules of EPA (3.5 g/d) for Studies 1 \& 2.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA
Description: A daily treatment of 5 identical capsules of DHA (1.75 g/d) for Studies 1 \& 2.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A daily treatment of 5 identical capsules of placebo (high oleic oil) in single or divided administration for Study 1.
Study: NCT05207332

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CHO+PRO
Description: A vegan product containing carbohydrate and protein

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CHO
Description: containing carbohydrate
Study: NCT02823184

Intervention type: BIOLOGICAL
Intervention: RNA sample of total leukocytes before start of treatment
Description: RNA sample of total leukocytes before start of treatment
Study: NCT02594098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
Study: NCT01657136

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: comparison of different drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta blocker
Description: comparison of different drugs
Study: NCT03472469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin 300mg PO every 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine patch every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine patch every 12 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: Opioid options include: Oral Opioids (Codeine, Tramadol, Hydrocodone, Oxycodone, Methadone, Morphine, Hydromorphone); Transdermal Opioid (Fentanyl); Intravenous Opioids (Morphine, Hydromorphone, Fentanyl)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: Opioid options include: Oral Opioids (Codeine, Tramadol, Hydrocodone, Oxycodone, Methadone, Morphine, Hydromorphone); Transdermal Opioid (Fentanyl); Intravenous Opioids (Morphine, Hydromorphone, Fentanyl)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regional anesthesia
Description: Regional anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regional anesthesia
Description: Regional anesthesia
Study: NCT02661542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10502-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10502-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10502-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10502-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10502-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10502-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10502-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10502-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10502-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10502-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF-10502-01
Study: NCT03730493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teaching subjects regarding self-care of PIVC with Pictorial Flashcard.
Description: In the experimental group researcher explained self-care of PIVC using pictorial flashcard on one to one basis. Patients were explained Do's and Don'ts, they have to keep in mind during self-care or management. Doubts of the patients were also addressed simultaneously. After this a copy of pictorial flashcard was given to the subjects to be used in future (during PIVC in-situ). In control group, standard care was given as per the hospital protocol. After 24 hours/one day, PIVC was observed for presence of any complications such as Phlebitis, Infiltration, Pain, Blockage and Dislodgement using V.I.P. Score, Infusion nurses society infiltration scale, Universal pain assessment tool and PIVC Documentation Tool and need for PIVC removal was also assessed. After 72 hours PIVC removed (whatever applicable) site of PIVC was reassessed, reason for removal was recorded and indwelling time was noted.
Study: NCT03392805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity
Description: beginning of regular physical activity under the supervision of a coach
Study: NCT03960359

Intervention type: OTHER
Intervention: Clinical, microbiological and inflammatory phenotype
Description: Clinical phenotype: temporal pattern of wheeze (EVW, SIW, MTW), history and clinical data, allergy diagnosis work-up Microbiological phenotype: viral status (PCR in nasal swab sample), bacteriological status (culture of induced sputum) Inflammatory phenotype: profile of cytokines, phenotype of immune cells in the blood and the sputum, cytokine response to TLR ligands by peripheral blood mononuclear cells.

Intervention type: OTHER
Intervention: Clinical, microbiological and inflammatory phenotype
Description: Clinical phenotype: temporal pattern of wheeze (EVW, SIW, MTW), history and clinical data, allergy diagnosis work-up Microbiological phenotype: viral status (PCR in nasal swab sample), bacteriological status (culture of induced sputum) Inflammatory phenotype: profile of cytokines, phenotype of immune cells in the blood and the sputum, cytokine response to TLR ligands by peripheral blood mononuclear cells.
Study: NCT02841449

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypohydrated
Description: Participants remain hypohydrated after the heat tent procedure

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehydrated
Description: Participants rehydrate after the heat tent procedure
Study: NCT02159352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Study: NCT01604824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: SC injection in the abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: SC injection in the abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: SC injection in the abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: SC injection in the abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injection in the abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injection in the abdomen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC injection in the abdomen
Study: NCT00805961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 10mg by mouth daily, beginning Week 11
Study: NCT04546880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing exercises
Description: Breathing exercises consist of the techniques of diaphragmatic and pursed-lip breathing. During the diaphragmatic breathing, attention is focused on the correct abdominal breathing.~The pursed-lip breathing is one step further to the diaphragmatic breathing and a technique designed to have control time and volume over breathing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stabilization exercises
Description: Training about the concepts of stabilization and abdominal bracing is given before starting to the study. The motor control tests for local muscles transversus abdominus and multifidi are performed after the training. The abdominal bracing test is performed in the quadruped position, in prone, and in hook lying position with the patient's spine supine with hips and knees flexed and knees in contact with the surface.~The second stage consists of closed-chain segmental control exercises. It is a series of weight-bearing exercises are performed on stable and unstable surfaces. The last stage of the stabilization program is an open kinetic chain exercise to promote distal stability.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stabilization exercises
Description: Training about the concepts of stabilization and abdominal bracing is given before starting to the study. The motor control tests for local muscles transversus abdominus and multifidi are performed after the training. The abdominal bracing test is performed in the quadruped position, in prone, and in hook lying position with the patient's spine supine with hips and knees flexed and knees in contact with the surface.~The second stage consists of closed-chain segmental control exercises. It is a series of weight-bearing exercises are performed on stable and unstable surfaces. The last stage of the stabilization program is an open kinetic chain exercise to promote distal stability.
Study: NCT04539652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Experimental group are treated with TenofoBell®
Study: NCT02655705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A
Description: Male 200 mg/day, Female 150 mg/day for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Initial dose with 10 mg/week, increasing 2.5 mg every 2 weeks up to 15 mg/week maintenance dose
Study: NCT02132793

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anger Management Therapy
Description: Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anger Management Therapy & RELAX app
Description: Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment. RELAX app (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through implementing an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors; and (4) supports communication and direction by the therapist through a web-based therapist interface and a remote and secure patient data server.
Study: NCT00408083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MultiHance
Description: 0.5 mmol/kg as a single dose administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnevist
Description: 0.5 mmol/kg as a single dose administration
Study: NCT01296997

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium phosphate
Description: the subjects consumed for 3 weeks a bread enriched with 1 g pentacalcium phosphate per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the subjects consumed a bread without pentacalcium phosphate
Study: NCT00551018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicriviroc
Description: one 30 mg tablet QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine and tenofovir disoproxil fumarate
Description: one 200/300 combination tablet QD
Study: NCT01199016

Intervention type: PROCEDURE
Intervention: Tympanocentesis
Description: To be performed as needed on children presenting with acute otitis media

Intervention type: PROCEDURE
Intervention: Nose/throat swab
Description: To be performed at every study visit

Intervention type: BIOLOGICAL
Intervention: Observational
Description: Observational Study Only
Study: NCT01313585

Intervention type: DRUG
Intervention: Initiation of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device

Intervention type: DRUG
Intervention: Initiation of beclometasone via the Easibreathe device plus salbutamol via and MDI device

Intervention type: DRUG
Intervention: Increase of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device

Intervention type: DRUG
Intervention: Increase of beclometasone via the Easibreathe device plus salbutamol via an MDI
Study: NCT00437359

Intervention type: DRUG
Group type: OTHER
Intervention: Toremifene citrate
Description: Toremifene citrate: 40-mg tablets by mouth once daily.

Intervention type: DRUG
Group type: OTHER
Intervention: Anastrozole
Description: Anastrozole: 1-mg tablets by mouth once daily.
Study: NCT02594865

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucerna
Description: Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fresubin
Description: Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.
Study: NCT02467478

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: 5 mg tablet once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily for 12 weeks
Study: NCT00478244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Day -9 through Day -6: 1.1 mg/kg if \< 12 kg IV every 6 hours; 0.8 mg/kg if \> 12 kg.
Study: NCT01960543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl 15 microg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl 15 microg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 7 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 9 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 7 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 9 mg
Study: NCT02387164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alum-GAD
Description: Two doses à 20 microgram 30 days apart subcutaneously administrated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 2000 Units (IE) (50 microgram) vitamin D3 daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: 2000 Units (IE) (50 microgram) vitamin D3 daily
Study: NCT04688541

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optitip Catheter (LinC Medical)
Description: The Optitip catheter, unlike the Foley catheter design which has a protruding tip, the Optitip has a blunt open end (eyelet) that protrudes slightly beyond a single fluid-filled 10ml balloon. It has an additional drainage eyelet underneath the balloon.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optitip Catheter (LinC Medical)
Description: The Optitip catheter, unlike the Foley catheter design which has a protruding tip, the Optitip has a blunt open end (eyelet) that protrudes slightly beyond a single fluid-filled 10ml balloon. It has an additional drainage eyelet underneath the balloon.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: Foley catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter
Description: Foley catheter
Study: NCT03695380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered at a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle (Stage 1) and PO QD on Days 1-21 (21/7 schedule) at the established dose for the doublet regimen in Stage 1 (Stage 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered at a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle (Stage 1) and PO QD on Days 1-21 (21/7 schedule) at the established dose for the doublet regimen in Stage 1 (Stage 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered at a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle (Stage 1) and PO QD on Days 1-21 (21/7 schedule) at the established dose for the doublet regimen in Stage 1 (Stage 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered at a starting dose of 60 mg by mouth (PO) daily (QD) on Days 1-21 of each 28-day cycle (Stage 1) and PO QD on Days 1-21 (21/7 schedule) at the established dose for the doublet regimen in Stage 1 (Stage 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered at a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle (Stage 1) and PO QD on Days 1-28 of each 28-day cycle at the established dose for the doublet regimen in Stage 1 (Stage 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered at a starting dose of 200 mg of niraparib PO QD on Days 1-28 of each 28-day cycle (Stage 1) and PO QD on Days 1-28 of each 28-day cycle at the established dose for the doublet regimen in Stage 1 (Stage 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered by IV infusion at the fixed dose of 840 mg on Days 1 and 15 (+/-3 days) of each 28-day cycle (Stages 1 and 2).
Study: NCT03739645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin conductance levels and slopes over time in conditioned fear as metrics.as metrics for anxiety
Description: After fear conditioning the cue induces autonomic responses like skin conductance and cognitive ratings like expectancy of the unconditioned stimulus after cueing or conditioning. Activity across blocks in the conditioning stage shows that the skin conductance can be described by levels, and slopes which might be related to state anxiety and trait anxiety (Spielberger trait and state anxiety inventory or questionnaire). These skin conductance measures may be concrete metrics for psychological processes in healthy subjects. We will carry out a partial correlation analysis of levels, state anxiety and trait anxiety, and then a similar analysis of slopes, state anxiety and trait anxiety. These results may show that concrete skin conductance levels and slopes are related to metrics of subjective self report measures of state and trait anxiety.
Study: NCT02363374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction Chemotherapy arm A
Description: Patients receive three induction chemotherapy cycles, starting on day 1, 15 and 29, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv~After a break of two weeks, radiotherapy starts combined with:~5-FU: 250 mg/sqm per day, iv, on day 43-57, day 64-77 Oxaliplatin: 50 mg/sqm, day 43, 50, 64, and 71

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation arm A
Description: Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 43 -80

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation arm B
Description: Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy arm B
Description: chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29.~After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of:~Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery should be performed about 5 (arm B) or 6 (arm A) weeks after the last radiation or chemotherapy, i.e. around day 123

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery should be performed about 5 (arm B) or 6 (arm A) weeks after the last radiation or chemotherapy, i.e. around day 123
Study: NCT00545220

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: problem-solving training

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham intervention
Study: NCT04231214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol-Tiotropium
Description: 5µg Olodaterol and 5 µg Tiotropium via the soft mist inhaler Respimat®, administered once on Day 1 or Day 9 and daily from Day 10 to Day 24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol-Tiotropium
Description: 5µg Olodaterol and 5 µg Tiotropium via the soft mist inhaler Respimat®, administered once on Day 1 or Day 9 and daily from Day 10 to Day 24
Study: NCT01340781

Intervention type: PROCEDURE
Intervention: Polysomnogram
Description: An attended polysomnogram will be conducted in the subjects room during an in patient hospital stay